Preferred Label : Tabelecleucel;

NCIt synonyms : EBV-CTLs; CTLs ATA129; Allogeneic EBV-specific CTLs ATA129; Allogeneic EBV-specific Cytotoxic T-lymphocytes;

NCIt definition : Allogeneic cytotoxic T-lymphocytes (CTLs) selective for the tumor-associated antigens (TAAs) expressed by the Epstein-Barr virus (EBV), with potential immunostimulating and antineoplastic activities. Upon administration, and after hematopoietic cell transplants (HCT) or solid organ transplants (SOT), or during certain other immunocompromised states, tabelecleucel targets and binds to EBV-associated antigens expressed on EBV-infected cells. This results in lysis of EBV-infected cells and prevents growth of EBV-associated cancer cells. EBV is associated with a variety of cancers and post-transplant lymphoproliferative disorders (EBV PTLD).;

UNII : G3NJ7M8N4H;

Drug name : Teb-cel; Tab-cel; Ebvallo;

Molecule name : ATA-129; ATA 129;

NCI Metathesaurus CUI : CL541621;

Codes from synonyms : 114494;

Details


Main resources

You can consult :


https://www.ema.europa.eu/en/medicines/human/EPAR/ebvallo
2023
false
false
false
Netherlands
French
English
treatment outcome
treatment outcome
syndication feed
syndication feed
summary of product characteristics
summary of product characteristics
package leaflet
package leaflet
drug evaluation
drug evaluation
drug approval
drug approval
europe
europe
Tabelecleucel
Tabelecleucel
Tabelecleucel
Tabelecleucel
orphan drug production
orphan drug production
adult
adult
child
child
adolescent
adolescent
EBV-Related Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative Disorder
transplantation
transplantation
lymphoproliferative disorders
lymphoproliferative disorders
injections, intravenous
injections, intravenous
epstein-barr virus infections
epstein-barr virus infections
Antineoplastic Agents, Immunological
Antineoplastic Agents, Immunological
product surveillance, postmarketing
product surveillance, postmarketing
immunotherapy, adoptive
immunotherapy, adoptive
lymphocyte transfusion
lymphocyte transfusion
pregnancy
pregnancy
breast feeding
breast feeding
drug evaluation, preclinical
drug evaluation, preclinical
t-lymphocytes
t-lymphocytes
tabelecleucel
tabelecleucel

---
https://www.has-sante.fr/jcms/p_3447489/fr/ebvallo-tabelecleucel-hemopathie-maligne
2023
false
false
false
France
treatment outcome
treatment outcome
insurance, health, reimbursement
insurance, health, reimbursement
Tabelecleucel
Tabelecleucel
Adoptive Cell Therapy Agent
Adoptive Cell Therapy Agent
adult
adult
child
child
adolescent
adolescent
EBV-Related Post-Transplant Lymphoproliferative Disorder
EBV-Related Post-Transplant Lymphoproliferative Disorder
Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Refractory Neoplastic Post-Transplant Lymphoproliferative Disorder
Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder
Recurrent Neoplastic Post-Transplant Lymphoproliferative Disorder
tabelecleucel
tabelecleucel
evaluation of the transparency committee
evaluation of the transparency committee
Malignant hemopathy
Malignant hemopathy
hematologic neoplasms
hematologic neoplasms

---
https://www.has-sante.fr/jcms/p_3451087/fr/
2023
France
evaluation of the transparency committee
hematologic neoplasms
hematologic diseases
Tabelecleucel

---
https://www.has-sante.fr/jcms/p_3451087/fr/ebvallo-tabelecleucel-hemopathie-maligne
2023
false
false
false
France
French
evaluation of the transparency committee
evaluation of the transparency committee
Tabelecleucel
Tabelecleucel

---
https://ansm.sante.fr/tableau-acces-derogatoire/ebvallo
2023
false
false
false
France
French
drug information
Tabelecleucel

---
Nous contacter.
29/10/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.